Audit: QRS - Sorbitol for Health & Longevity

Audit conducted on 11/06/2026 08:23 using AI4L + evidence-mcp / Opus 5.5

Iterations

Summary

Items Count
Total 97
Passed 87
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Lede, Protocol, Time to effect, gates, tiers, markers and cadence all trace to ER passages (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions, Monitoring).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Hedges kept: “no study compared it with a placebo”, “apparently”, “inferred, no human data on dietary sorbitol”, “findings conflict on absorption”, “No established target”.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No claim strengthened or softened.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications from ER “Populations who should avoid”; interactions from “Documented”/”Theoretical” groups; tiers from Expected Benefits / Potential Risks.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, citations, NCT IDs or brand names (e.g., Kayexalate) in the QRS.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢  
2.2 The tone of the QRS is expert, accessible, objective, and data-driven 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢  
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢  
2.6 The QRS never addresses the reader directly — it presents evidence, not guidance 🟢 No second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms (Anuria, Biallelic SORD variants, sodium polystyrene sulfonate, colonic necrosis) are ER labels carried verbatim.
2.8 Information is presented in a concise and very compact manner 🟢  
2.9 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.10 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.11 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.12 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢  
2.13 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” wording.
2.14 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. 🟢 “Oral single dose” used; no lay route wording.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢  
3.2 Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name 🟢 All template variables present; marker_# expanded to 1–5, qualitative_item_# to 1–4.
3.3 Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well 🟢 Diff against template shows changes only inside data-qrs-var spans, display:none on empty tier spans, and the filled metadata block (plus workflow keys duration/git_user/git_issue).

4. Formatting

# Description Result Comments
4.1 An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. 🟢 Empty High benefit and Medium risk tiers hidden; no empty-state text.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels “Laxative regimen (trial)”, “Laxative regimen (prescribing information)”, “Sweetener use” and gate labels match ER bold labels.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Example lists trimmed with ER words kept (Other polyols, Other osmotic laxatives).
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢  
4.5 The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. 🟢 No trailing dash clause, gloss, untrimmed optional example list or repetition found.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢  
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢  
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢  
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration is quoted; its value contains a colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢  
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 26.10.25 matches QRS.md.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 2026-1106-0740
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢  
5.9 The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name 🟢  
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢  
5.11 The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model 🟢  
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢  

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢  
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢  
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 11/06/2026
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢  
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢  

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence 🟢 Opens “Sorbitol, a sugar alcohol in fruit, sugar-free products and medicines, is also an inexpensive laxative.”
7.2 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢  
7.3 [at_a_glance] is no longer than 70 words 🟢 69 words.
7.4 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢  
7.5 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢  
7.6 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢  
7.7 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢  

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
8.2 [stop_items] represent the Contraindications from the ER 🟢 All six ER populations listed.
8.3 Individual [stop_items] are formatted as <li></li> 🟢  
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Severity qualifier “absolute contraindication” kept; dropped parentheticals are glosses, not qualifiers.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 Section populated.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A Section not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢  
9.2 [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found 🟢 Sodium polystyrene sulfonate (contraindication), acyclovir and digoxin (no interaction) correctly excluded; remaining eight listed.
9.3 [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label 🟢 All six theoretical interactions listed.
9.4 The ER placeholder “None identified” is never an item: it means that group is empty 🟢  
9.5 Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause 🟢  
9.6 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢  
9.7 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢  
9.8 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A ER uses no ranking notation.
9.9 If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. N/A ER theoretical group is not empty.
9.10 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 Section populated.
9.11 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. N/A Section not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Therapeutic Protocol section 🟢  
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from that section 🟢  
10.3 If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. N/A ER provides at least three actionable aspects.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. 🟢  

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Laxative onset, constipation response and caries effects from ER Practical Considerations.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Constipation-related (Medium) sets precede caries (Low).
11.3 If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. N/A ER provides three time-to-effect aspects.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢  
11.5 If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢  
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢  
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
12.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 benefits_high hidden with display:none.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢  
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢  
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢  
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢  
13.5 If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 risks_medium hidden with display:none.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
14.2 All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names 🟢 All five ER biomarkers listed.
14.3 [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” 🟢  
14.4 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. 🟢  
14.5 If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template N/A ER names measurable biomarkers.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring Protocol & Defining Success section 🟢  
15.2 All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … 🟢 All four qualitative markers listed.
15.3 If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template N/A ER names qualitative markers.

Issues 11/06/2026 08:23

Pass rate 100.00%. No issues found.

Issues 11/06/2026 08:21

  1. 9.6 — Theophylline study detail kept: The Theophylline (slow-release) item at line 564 carries “when sorbitol is added to repeated activated charcoal”, the set-up of a single crossover study, which is study detail and narrows a fact the ER also reports without charcoal.

Fixes 11/06/2026 08:21

  1. 9.6 — Theophylline study detail kept: Shortened the Theophylline (slow-release) item from “lower blood levels when sorbitol is added to repeated activated charcoal” to “lower blood levels”.

Issues 11/06/2026 08:18

  1. 2.14 — Lay term in lede: The At a Glance text at line 439 says “no study compared it with a dummy treatment”, a consumer-grade phrase where the ER uses the formal term “placebo” (“no placebo-controlled study exists”).

Fixes 11/06/2026 08:18

  1. 2.14 — Lay term in lede: Replaced “no study compared it with a dummy treatment” with “no study compared it with a placebo” in the At a Glance text (now 69 words).

Issues 11/06/2026 08:14

  1. 7.5 — Clinical-register terms in lede: The At-A-Glance at line 439 uses “no placebo-controlled study exists” and “flatulence”, terms a non-specialist would not use unprompted; plain alternatives (e.g., “gas”, a comparison with a dummy treatment) are needed.

Fixes 11/06/2026 08:14

  1. 7.5 — Clinical-register terms in lede: Replaced “no placebo-controlled study exists” with “no study compared it with a dummy treatment” and “flatulence” with “gas” in the At-A-Glance; tightened wording elsewhere to stay at 70 words.

Issues 11/06/2026 08:10

  1. 2.7 — Jargon in protocol sub: action_1_sub at line 456 reads “Titrated for chronic constipation in older men”; “titrated” is medical jargon outside any ER label, which the ER itself glosses as “dose adjusted to response”.
  2. 2.14 — Colloquial terms in lede: The at_a_glance text at line 439 uses consumer-grade “gas” instead of “flatulence” and “blood-sugar” instead of “blood-glucose”.

Fixes 11/06/2026 08:10

  1. 2.7 — Jargon in protocol sub: Changed action_1_sub from “Titrated for chronic constipation in older men” to “Dose adjusted to response for chronic constipation in older men”, using the ER’s own gloss.
  2. 2.14 — Colloquial terms in lede: Replaced “gas” with “flatulence” and “blood-sugar” with “blood-glucose” in at_a_glance; word count stays at 70.

Issues 11/06/2026 08:05

  1. 7.5 — Clinical term in lede: The At a Glance text at line 439 uses “flatulence”, a clinical-register word; the ER Conclusion uses the plain-language “gas”.

Fixes 11/06/2026 08:05

  1. 7.5 — Clinical term in lede: Replaced “flatulence” with “gas” in the At a Glance text, matching the ER Conclusion wording (word count stays at 70).

Issues 11/06/2026 08:01

  1. 2.7 — Pharmacokinetic jargon in interactions: The Key Interactions items at lines 561 and 564 say “lower drug exposure” / “lower exposure” instead of the plain “lower drug blood levels”.
  2. 2.14 — Colloquial term in lede: The lede at line 439 uses “gas” in “Bloating, gas and diarrhea rise with dose” instead of the formal “flatulence”.

Fixes 11/06/2026 08:01

  1. 2.7 — Pharmacokinetic jargon in interactions: Replaced “lower drug exposure” with “lower drug blood levels” (oral drug solutions) and “lower exposure” with “lower blood levels” (theophylline).
  2. 2.14 — Colloquial term in lede: Changed “Bloating, gas and diarrhea” to “Bloating, flatulence and diarrhea” in the lede (word count unchanged at 70).

Issues 11/06/2026 07:58

  1. 1.1 — Plural trials unsupported: time_3_sub (line 517) reads “Accrued in sorbitol gum trials”, but the ER’s Time to effect bullet ties the 2–3 year caries effect to a single trial (Machiulskiene 2001).

Fixes 11/06/2026 07:58

  1. 1.1 — Plural trials unsupported: Changed time_3_sub from “Accrued in sorbitol gum trials” to “Accrued in a sorbitol gum trial”, matching the single trial the ER cites.

Issues 11/06/2026 07:54

  1. 7.2 — Lede omits key danger: The at_a_glance text at line 439 leaves out the ER Conclusion’s statement that sorbitol “is dangerous for people with inherited fructose intolerance”, the main execution-relevant safety fact beyond dose-dependent GI symptoms.

Fixes 11/06/2026 07:54

  1. 7.2 — Lede omits key danger: Added “inherited fructose intolerance makes it dangerous” to at_a_glance and tightened wording elsewhere (“sugar-free products”, “costlier option”, “chewing apparently drives most dental gains”) to stay within 70 words.

Issues 11/06/2026 07:51

  1. 2.7 — Jargon in marker rationale: marker_1_why at line 631 reads “Unexplained loss signals chronic osmotic diarrhea”; “osmotic” is unnecessary medical jargon outside any ER label.

Fixes 11/06/2026 07:51

  1. 2.7 — Jargon in marker rationale: Changed marker_1_why from “Unexplained loss signals chronic osmotic diarrhea” to “Unexplained loss signals chronic diarrhea”.

Issues 11/06/2026 07:50

  1. 1.3 — Dental verdict softened in lede: The at-a-glance at line 439 says “chewing itself may drive dental gains”, while the ER Conclusion says dental gains “appear to come largely from chewing gum itself” (Expected Benefits: “chewing, not sorbitol, likely drives the effect”), so the QRS understates the ER’s doubt about sorbitol’s own dental effect.

Fixes 11/06/2026 07:50

  1. 1.3 — Dental verdict softened in lede: Replaced “though chewing itself may drive dental gains” with “chewing appears to drive most dental gains” in the at-a-glance, matching the ER’s “appear to come largely from chewing gum itself” while staying within 70 words.

Issues 11/06/2026 07:45

  1. 1.1 — Common practice attributed to trial: The “Laxative regimen (trial)” sub-line at line 456 adds “single daily dose, morning or early evening”, which the ER presents as common-practice timing (Therapeutic Protocol intro, “Time of day”, “Single or split dosing”), not as part of the Lederle 1990 trial regimen.

Fixes 11/06/2026 07:45

  1. 1.1 — Common practice attributed to trial: Removed “; single daily dose, morning or early evening” from action_1_sub, so the “Laxative regimen (trial)” cell now reads only “Titrated for chronic constipation in older men”, as the ER states for Lederle 1990.

Issues 11/06/2026 07:41

  1. 1.3 — Lede drops dental caveat: The At-A-Glance at line 439 says “Gains for teeth and blood sugar come mainly from replacing sugar” but omits the ER Conclusion’s qualifier that “the dental gains appear to come largely from chewing gum itself” (ER line 423), overstating sorbitol’s own dental benefit.

Fixes 11/06/2026 07:41

  1. 1.3 — Lede dental caveat restored: Changed “Gains for teeth and blood sugar come mainly from replacing sugar.” to “…come mainly from replacing sugar, though chewing itself may drive dental gains.” and tightened the opening sentence to stay within 70 words.